177 related articles for article (PubMed ID: 9636912)
21. The antithrombin III-saving effect of reduced systemic heparinization and heparin-coated circuits.
Ranucci M; Cazzaniga A; Soro G; Isgrò G; Frigiola A; Menicanti L
J Cardiothorac Vasc Anesth; 2002 Jun; 16(3):316-20. PubMed ID: 12073203
[TBL] [Abstract][Full Text] [Related]
22. Completely heparinized cardiopulmonary bypass and reduced systemic heparin: clinical and hemostatic effects.
Ovrum E; Holen EA; Tangen G; Brosstad F; Abdelnoor M; Ringdal MA; Oystese R; Istad R
Ann Thorac Surg; 1995 Aug; 60(2):365-71. PubMed ID: 7646097
[TBL] [Abstract][Full Text] [Related]
23. Synthetic protein treated versus heparin coated cardiopulmonary bypass surfaces: similar clinical results and minor biochemical differences.
Wimmer-Greinecker G; Matheis G; Martens S; Oremek G; Abdel-Rahman U; Moritz A
Eur J Cardiothorac Surg; 1999 Aug; 16(2):211-7. PubMed ID: 10485423
[TBL] [Abstract][Full Text] [Related]
24. Coronary artery bypass surgery with heparin-coated perfusion circuits and low-dose heparinization.
Mullen JC; Bentley MJ; Gelfand ET; Koshal A; Modry DL; Guenther CR; Etches WS; Stang LJ; Lopushinsky SR
Can J Surg; 2002 Jun; 45(3):166-72. PubMed ID: 12067167
[TBL] [Abstract][Full Text] [Related]
25. Perioperative course and recovery after heparin-coated cardiopulmonary bypass: low-dose versus high-dose heparin management.
Weiss BM; von Segesser LK; Turina MI; Seifert B; Pasch T
J Cardiothorac Vasc Anesth; 1996 Jun; 10(4):464-70. PubMed ID: 8776638
[TBL] [Abstract][Full Text] [Related]
26. Cardiopulmonary bypass parameters and hemostatic response to cardiopulmonary bypass in infants versus children.
Eisses MJ; Chandler WL
J Cardiothorac Vasc Anesth; 2008 Feb; 22(1):53-9. PubMed ID: 18249331
[TBL] [Abstract][Full Text] [Related]
27. Comparison of polymethoxyethylacrylate-coated circuits with leukocyte filtration and reduced heparinization protocol on heparin-bonded circuits in different risk cohorts.
Gunaydin S; McCusker K; Vijay V; Isbir S; Sari T; Onur MA; Gurpinar A; Sezgin A; Sargon MF; Tezcaner T; Zorlutuna Y
Perfusion; 2006 Nov; 21(6):329-42. PubMed ID: 17312857
[TBL] [Abstract][Full Text] [Related]
28. Haemostasis at low heparin dosage during cardiopulmonary bypass with heparin-coated circuits in pigs.
Bagge L; Borowiec JW; Thelin S; Hultman J
Scand Cardiovasc J; 1997; 31(5):275-81. PubMed ID: 9406294
[TBL] [Abstract][Full Text] [Related]
29. A comparative evaluation of the effect of pump type and heparin-coated surfaces on platelets during cardiopulmonary bypass.
Misoph M; Babin-Ebell J; Schwender S
Thorac Cardiovasc Surg; 1997 Dec; 45(6):302-6. PubMed ID: 9477463
[TBL] [Abstract][Full Text] [Related]
30. An ex vivo evaluation of blood coagulation and thromboresistance of two extracorporeal circuit coatings with reduced and full heparin dose.
Teligui L; Dalmayrac E; Mabilleau G; Macchi L; Godon A; Corbeau JJ; Denommé AS; Bouquet E; Boer C; Baufreton C
Interact Cardiovasc Thorac Surg; 2014 Jun; 18(6):763-9. PubMed ID: 24632424
[TBL] [Abstract][Full Text] [Related]
31. Coagulofibrinolysis during heparin-coated cardiopulmonary bypass with reduced heparinization.
Kumano H; Suehiro S; Hattori K; Shibata T; Sasaki Y; Hosono M; Kinoshita H
Ann Thorac Surg; 1999 Oct; 68(4):1252-6. PubMed ID: 10543488
[TBL] [Abstract][Full Text] [Related]
32. Comparative effects of pulsatile and nonpulsatile flow on plasma fibrinolytic balance in pediatric patients undergoing cardiopulmonary bypass.
Aĝirbaşli MA; Song J; Lei F; Wang S; Kunselman AR; Clark JB; Myers JL; Ündar A
Artif Organs; 2014 Jan; 38(1):28-33. PubMed ID: 24237252
[TBL] [Abstract][Full Text] [Related]
33. Biocompatibility of heparin-coated extracorporeal bypass circuits: new heparin bonded bioline system.
Tayama E; Hayashida N; Akasu K; Kosuga T; Fukunaga S; Akashi H; Kawara T; Aoyagi S
Artif Organs; 2000 Aug; 24(8):618-23. PubMed ID: 10971248
[TBL] [Abstract][Full Text] [Related]
34. Haemostasis at low heparin dosage during cardiopulmonary bypass with heparin-coated circuits in pigs.
Bagge L; Borowiec JW; Thelin S; Hultman J
Scand Cardiovasc J; 1997; 31(6):275-81. PubMed ID: 9498931
[TBL] [Abstract][Full Text] [Related]
35. Heparin-coated cardiopulmonary bypass circuits: hemostatic alterations and postoperative blood loss.
Wagner WR; Johnson PC; Thompson KA; Marrone GC
Ann Thorac Surg; 1994 Sep; 58(3):734-40; discussion 741. PubMed ID: 7944696
[TBL] [Abstract][Full Text] [Related]
36. The role of the protein C-thrombomodulin system and fibrinolysis during cardiovascular surgery: influence of acute preoperative plasmapheresis.
Menges T; Wagner RM; Welters I; Ruwoldt R; Boldt J; Hempelmann G
J Cardiothorac Vasc Anesth; 1996 Jun; 10(4):482-9. PubMed ID: 8776642
[TBL] [Abstract][Full Text] [Related]
37. Biocompatibility of poly2methoxyethylacrylate coating for cardiopulmonary bypass.
Noguchi M; Eishi K; Tada S; Yamachika S; Hazama S; Izumi K; Tanigawa K
Ann Thorac Cardiovasc Surg; 2003 Feb; 9(1):22-8. PubMed ID: 12667126
[TBL] [Abstract][Full Text] [Related]
38. A comparison of thromboelastography with heparinase or protamine sulfate added in vitro during heparinized cardiopulmonary bypass.
Spiess BD; Wall MH; Gillies BS; Fitch JC; Soltow LO; Chandler WL
Thromb Haemost; 1997 Aug; 78(2):820-6. PubMed ID: 9268178
[TBL] [Abstract][Full Text] [Related]
39. Centrifugal and roller pumps--are there differences in coagulation and fibrinolysis during and after cardiopulmonary bypass?
Steinbrueckner BE; Steigerwald U; Keller F; Neukam K; Elert O; Babin-Ebell J
Heart Vessels; 1995; 10(1):46-53. PubMed ID: 7730247
[TBL] [Abstract][Full Text] [Related]
40. Biocompatibility of heparin-coated circuits in pediatric cardiopulmonary bypass.
Kagisaki K; Masai T; Kadoba K; Sawa Y; Nomura F; Fukushima N; Ichikawa H; Ohata T; Suzuki K; Taketani S; Matsuda H
Artif Organs; 1997 Jul; 21(7):836-40. PubMed ID: 9212969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
